OCGN today
$0.92-$0.04 (-4.25%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourSymmetric Triangle
15 minBearish
5 minStrong Bullish
Daily trend turns up above $0.80
Key levels
Resistance$1.05
Resistance$0.97
Support$0.80
Support$0.69
Latest news & SEC filings
DealOcugen signs exclusive license deal with Celairis Therapeutics for OCU400
GuidanceOcugen sets 2027 timeline for trial data, flags funding doubt
All OCGN news →About Ocugen
Ocugen is a late-stage biotechnology company developing gene therapies for inherited retinal diseases and other forms of blindness. Its lead candidates include OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, all based on a modifier gene therapy approach. The company also develops OCU200 for diabetic eye complications, the NeoCart cartilage repair therapy, and inhaled mucosal vaccines for COVID-19 and influenza. It operates in the United States and works with partners and contract manufacturers to develop and produce its product candidates.
Based on the company's 10-K filed Mar 4, 2026.
Nasdaq · Healthcare
Ocugen, Inc. (OCGN)
What Is the Price Target for OCGN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is OCGN a Buy or Sell Right Now?
Thesis
- •Revenue growing 8.8% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OCGN.
Start Free Trial →Is OCGN Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
16
Moat Score
NONE
2/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with OCGN?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Musunuri Shankar | director officer | Sale | 468,727 | $525K | Sep 9, 2026 |
| Musunuri Shankar | director officer | Sale | 57,264 | $64K | Sep 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OCGN Growth Story
Revenue YoY
8.8%
3yr Revenue CAGR
21.1%
EPS Growth YoY
N/A
FCF Growth YoY
-25.5%
Revenue Trend
STRONG
Dark Pool Trades for OCGN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OCGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:40:11 | $0.92 | 5,000 | $$5K | BUY |
| 14:39:20 | $0.92 | 8,000 | $$7K | BUY |
| 14:38:33 | $0.92 | 2,197 | $$2K | SELL |
| 14:37:13 | $0.92 | 8,000 | $$7K | SELL |
| 14:37:13 | $0.92 | 8,000 | $$7K | SELL |
5 dark pool trades shown · $$29K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Ocugen, Inc. (OCGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OCGN — frequently asked questions
What is OCGN stock price today?
Ocugen, Inc. (OCGN) is at $0.92, down 4.25% (-$0.04) at the Nov 12, 2026 close.
Why is OCGN stock moving today?
Latest OCGN news — Nov 10, 2026: Ocugen signs exclusive license deal with Celairis Therapeutics for OCU400 · Nov 9, 2026: Ocugen sets 2027 timeline for trial data, flags funding doubt
What do analysts rate OCGN?
Analyst ratings for OCGN: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did OCGN beat earnings?
OCGN last reported on Aug 6, 2026: EPS -$0.07 vs -$0.05 expected — a miss of 31.3%.
Does OCGN pay a dividend?
OCGN does not currently pay a dividend.
What are OCGN support and resistance levels?
Support: $0.80, $0.69, $0.57. Resistance: $0.97, $1.05, $1.17.
What are insiders doing with OCGN?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on OCGN?
Nov 10, 2026: Ocugen signs exclusive license deal with Celairis Therapeutics for OCU400 · Nov 9, 2026: Ocugen sets 2027 timeline for trial data, flags funding doubt